RedHill Biopharma Gets Rights To Naloxegol, No Longer Core At AstraZeneca

Backed By Funds From HealthCare Royalty Partners

 
• By John Davis
Stomach
GI diseases are a focus for RedHill Biopharma • Source: Shutterstock

More from Deals

More from Business